Seeking Alpha

XTL Entered Definitive Agreement to Acquire The Social Proxy

Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, June 05, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has entered into a definitive ...

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcherCritical unmet need: 1 in 31 ...
Seeking Alpha

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

RAMAT GAN, ISRAEL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- August 14, 2024, XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has completed the acquisition of THE SOCIAL PROXY Ltd.
Nasdaq

XTL To Aquire The Social Proxy

RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd., ...
Investing

XTL acquires autism therapeutics firm NeuroNOS from Beyond Air

TEL AVIV/BOSTON - XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced Tuesday it has entered a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ:XAIR) focused ...
MarketWatch

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone ...